Summary of Shattuck Labs Q3 2023 Earnings Call

1Key Financial Results and Metrics

Cash Position: As of September 30, 2023, Shattuck Labs reported cash and cash equivalents of $101.1 million.

Expenses:

Research and Development (R&D) expenses were $24.2 million, up from $18.9 million in Q3 2022.

General and Administrative (G&A) expenses decreased to $5.1 million from $6.6 million in Q3 2022.

Net Loss: The net loss for Q3 2023 was $27.5 million, or $0.65 per share, compared to a net loss of $24.6 million, or $0.58 per share in Q3 2022.

Cash Runway: The company expects its cash reserves to fund operations through year-end 2024, excluding potential capital from business development or additional clinical costs.

2Strategic Updates and Business Highlights

Clinical Progress:

The lead product candidate, SL-172154, has shown promising interim data in ongoing clinical trials for platinum-resistant ovarian cancer (PROC) and acute myeloid leukemia (AML)/higher-risk myelodysplastic syndromes (MDS).

In the Phase 1B trial for PROC, an overall response rate of 27% was observed, significantly higher than the 4% benchmark from the JAVELIN Ovarian 200 trial.

The Phase 1A/B trial in AML/MDS has shown anti-leukemic activity, with one patient achieving a morphologic leukemia-free state.

Upcoming Presentations: Data from ongoing trials will be presented at the American Society of Hematology (ASH) Annual Meeting in December 2023.

3Forward Guidance and Outlook

Shattuck Labs anticipates completing enrollment in its ongoing trials by the end of Q4 2023, with further updates expected in early 2024.

The company aims to demonstrate superior response rates and durability compared to existing treatments, particularly in the TP53 mutant AML cohort and higher-risk MDS patients.

4Bad News, Challenges, or Points of Concern

Competitive Landscape: The CD47 pathway has faced skepticism due to safety issues with other agents, which could impact perceptions of SL-172154 despite its differentiated profile.

Enrollment Challenges: Initial enrollment in the PROC study was slow, partly due to the perception of PLD's efficacy. However, momentum has improved recently.

Clinical Risks: The company must demonstrate that SL-172154 can exceed the response rates of competing therapies to secure a favorable market position.

5Notable Q&A Insights

Patient Characteristics: The majority of patients in the PROC study had received multiple prior therapies, including platinum and bevacizumab, indicating a challenging patient population.

Efficacy Analysis: There is ongoing analysis regarding the correlation between prior treatments (e.g., PARP inhibitors) and patient responses, but it is too early to draw definitive conclusions.

Response Kinetics: Initial responses have been rapid, with some patients showing improvement within the first treatment cycle.

Regulatory Pathways: There is potential for accelerated approval in specific cohorts, such as TP53 mutant AML, if response rates exceed established benchmarks. This summary encapsulates the key elements from the earnings call, highlighting Shattuck Labs' financial standing, clinical advancements, future outlook, and challenges faced in a competitive landscape.